Stay updated on Viaskin Peanut in Young Children Clinical Trial

Sign up to get notified when there's something new on the Viaskin Peanut in Young Children Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Viaskin Peanut in Young Children Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T23:14:20.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the safety and efficacy of Viaskin Peanut in inducing desensitization to peanut in peanut-allergic children aged 1 to 3 years after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
    Difference
    0.1%
    Check dated 2024-06-06T14:44:42.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying requirements such as age, physician-diagnosed peanut allergy, and specific IgE levels. Previously, no information was provided regarding participation criteria for collaborators and investigators.
    Difference
    9%
    Check dated 2024-05-22T21:21:54.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:36:33.000Z thumbnail image

Stay in the know with updates to Viaskin Peanut in Young Children Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Viaskin Peanut in Young Children Clinical Trial page.